Defining prostate cancer risk after radical prostatectomy

European Journal of Surgical Oncology

Volumn 40, Issue 5, 2014, Pages 496-504

  Adamis, S ^a   Varkarakis, I M ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Adverse features; Predictive nomograms; Prostate cancer; Radical prostatectomy

Indexed keywords

CANCER RECURRENCE; CANCER RISK; GLEASON SCORE; HUMAN; LYMPH VESSEL METASTASIS; NOMOGRAM; PERINEURAL INVASION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEMINAL VESICLE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR INVASION; TUMOR VOLUME;

ADVERSE FEATURES; PREDICTIVE NOMOGRAMS; PROSTATE CANCER; RADICAL PROSTATECTOMY;

CARCINOMA; HUMANS; KALLIKREINS; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 84897443236     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.02.221     Document Type: Review

References (82)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics 2010 CA Cancer J Clin 60 2010 277 300
2. M. Quinn, and P. Babb Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I international comparisons BJU Int 90 2002 162 173
3. P. Boyle, and J. Ferlay Cancer incidence and mortality in Europe 2004 Ann Oncol 16 3 2005 481 488
4. C. Mettlin, G.P. Murphy, and R.J. Babaian et al. Observation on the early detection of prostate cancer from the American Cancer Society - National Prostate Cancer Detection Project Cancer 80 1997 1814 1817
5. A. Farkas, D. Schneider, M. Perrotti, C.B. Cummings, and W.S. Wars National trends in the epidemiology of prostate cancer, 1973 to 1984: evidence for the effectiveness of prostate specific antigen screening Urology 52 1986 444 449
6. M.R. Cooperberg, D.P. Lubeck, S.S. Mehla, and P.R. Carroll Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol 170 2009 S21 S25
7. M.A. Khan, and A.W. Partin Management of high-risk populations with locally advanced prostate cancer Oncologist 8 2003 259 269
8. R.J. Babaian, P. Troncoso, V.A. Bhadkamkar, and D.A. Johnston Analysis of clinicopathologic factors predicting outcome after radical prostatectomy Cancer 81 2001 1414 1422
9. C.T. Nguyen, A.M. Reuther, A.J. Stephenson, E.A. Klein, and J.S. Jones The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival J Urol 181 2009 75 80
10. S. Loeb, E.M. Schaeffer, B.J. Trock, J.L. Epstein, E.B. Humphreys, and P.C. Walsh What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 76 3 2010 710 714
11. J.F. Ward, H. Zincke, E.J. Bergstrahl, J.M. Slezak, R.P. Myers, and M.L. Blute The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy J Urol 172 2004 1328 1332
12. A.J. Stephenson, P.T. Scardino, and J.A. Eastham et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy J Clin Oncol 23 2005 7005 7012
13. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
14. S.J. Freedland, E.B. Humphreys, and L.A. Mangold et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439
15. D.F. Gleason, and G.T. Mellinger Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging J Urol 167 2002 953 958
16. P. Harnden, M.D. Shelley, B. Coles, J. Staffurth, and M.D. Mason Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis Lancet Oncol 8 2007 411 419
17. H.G. Sim, D. Telesca, and S.H. Culp et al. Tertiary Gleason pattern 5 in Gleason7 prostate cancer predicts pathological stage and biochemical recurrence J Urol 179 2008 1775 1779
18. O. Alenda, G. Ploussard, and P. Mouracade et al. Impact of the primary Gleason pattern on biochemical recurrence-free survival after radical prostatectomy: a single-center cohort of 1,248 patients with Gleason 7 tumors World J Urol 29 5 2011 Oct 671 676
19. J.I. Epstein, M. Amin, and L. Boccon-Gibod et al. Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimens Scand J Urol Nephrol Suppl 216 2005 34 63
20. P. Swindle, J.A. Eastham, and M. Ohori et al. Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol 174 2005 903 907
21. J.A. Eastham, K. Kuroiwa, and M. Ohori et al. Prognostic significance of location of positive surgical margins in radical prostatectomy specimens Urology 70 2007 965 969
22. J. Pfitzenmaier, S. Pahernik, T. Tremmel, A. Haferkamp, S. Buse, and M. Hohenfellner Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int 102 2008 1413 1418
23. A.N. Vis, F.H. Schroeder, and T.H. van der Kwast The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer Eur Urol 50 2006 258 265
24. M.A. Simon, S. Kim, and M.S. Soloway Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins J Urol 175 2006 140 144
25. L. Cheng, M.F. Darson, E.J. Bergstrahl, J. Slezak, R.P. Myers, and D.G. Bostwick Correlation of margin status and extraprostatic extension with progression of prostate carcinoma Cancer 86 1999 1775 1782
26. S. Alkhateeb, S. Alibhai, and N. Fleshner et al. Impact of positive surgical margins after radical prostatectomy differs by disease risk group J Urol 183 2010 145 150
27. M. Sofer, K.L. Hamilton-Nelson, F. Civantos, and M.S. Soloway Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression J Urol 167 2002 2453 2456
28. R.A. Marks, M.O. Koch, A. Lopez-Beltran, R. Montironi, B.E. Juliar, and L. Cheng The relationship between the extend of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens Hum Pathol 38 2007 1207 1211
29. J.A. Pettus, C.J. Weight, C.J. Thompson, R.G. Middleton, and R.A. Stephenson Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location J Urol 172 2004 129 132
30. H. Aydin, T. Tsuzuki, D. Hernandez, P.C. Walsh, A.W. Parin, and J.I. Epstein Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression Urology 64 2004 551 555
31. W.A. Sakr, T.M. Wheeler, and M. Blute et al. Staging and reporting of prostate cancer - sampling of the radical prostatectomy specimen Cancer 78 1996 366 368
32. A.G. Ayala, J.Y. Ro, R. Babaian, P. Troncoso, and D.J. Grignon The prostatic capsule: does it exist? its importance in the staging and treatment of prostatic carcinoma Am J Surg Pathol 13 1989 21 27
33. G.P. Swanson, and J.W. Basler Prognostic factors for failure after prostatectomy J Cancer 2 2011 1 19
34. K.A. Roehl, M. Han, C.G. Ramos, J.A. Antenor, and W.J. Catalona Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results J Urol 172 2004 910 914
35. P.I. Karakiewicz, J.A. Eastham, and M. Graefen et al. Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients Urology 66 2005 1245 1250
36. V. Ravery, L.A. Boccon-Gibod, and A. Meulemans et al. Predictive value of pathological features for progression after radical prostatectomy Eur Urol 26 1994 197 201
37. S.R. Potter, J.I. Epstein, and A.W. Partin Seminal vesicle invasion: significance and therapeutic implications Rev Urol 2 3 2000 190 195
38. J.L. Epstein, M. Carmichael, and P.C. Walsh Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis J Urol 149 1993 1040 1045
39. M. Ohori, T.M. Wheeler, M.W. Kattan, Y. Goto, and P.T. Scardino Prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol 154 1995 1818 1824
40. L. Salomon, A.G. Anastasiadis, and C.W. Johnson et al. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression Urology 62 2003 304 309
41. J.L. Epstein, A.W. Partin, S.W. Potter, and P.C. Walsh Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters Urology 56 2000 283 288
42. T.J. Guzzo, M.A. Vira, and W. Neway et al. Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy Urology 69 6 2007 1147 1151
43. F.K. Chun, A. Briganti, and C. Jedres et al. Tumor volume and high grade tumor volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy Eur J Cancer 43 3 2007 536 543
44. L. Salomon, O. Levrel, and A.G. Anastasiadis et al. Prognostic significance of tumor volume after radical prostatectomy: a multivariate analysis of pathological prognostic factors Eur Urol 43 2003 39 44
45. E.N. Rampersaud, L. Sun, J.W. Moul, J. Madden, and S.J. Freedland Percent tumor involvement and risk of biochemical progression after radical prostatectomy J Urol 180 2008 571 576
46. I.M. Thompson, S. Salem, and S.S. Chang et al. Tumor volume as a predictor of adverse pathologic features and biochemical recurrence (BCR) in radical prostatectomy specimens: a tale of two methods World J Urol 29 2011 15 20
47. J. Endrizzi, and T. Seay The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer Br J Urol 85 2000 696 699
48. J.I. Epstein The role of perineural invasion and other bio-characteristics as prognostic markers for localized prostate cancer Sem Urol Oncol 16 1998 124 128
49. J.P. Brooks, P.S. Albert, J. O'Connell, D.G. McLeod, and M.M. Poggi Lymphovascular invasion in prostate cancer: prognostic significance in patients treated with radiotherapy after radical prostatectomy Cancer 106 2006 1521 1526
50. S.F. Shariat, S.M. Khoddami, and H. Saboorian et al. Lymphovascular invasion is a pathological feature of biologically aggressive disease in patients treated with radical prostatectomy J Urol 171 2004 1122 1127
51. M. May, O. Kaufmann, F. Hammermann, V. Loy, and M. Siegsmund Prognostic impact of lymphovascular invasion in radical prostatectomy specimens BJU Int 99 2006 539 544
52. C.M. Herman, G.E. Wilcox, M.W. Kattan, P.T. Scardino, and T.M. Wheeler Lymphovascular invasion as a predictor of disease progression in prostate cancer Am J Surg Pathol 24 2000 859 863
53. A. De la Taille, M.A. Rubin, and R. Buttyan et al. Is microvascular invasion on radical prostatectomy specimen a useful predictor of PSA recurrence for prostate cancer patients? Eur Urol 38 2000 79 84
54. D. Van den Ouden, R. Kranse, W.C. Hop, T.H. van der Kwast, and F.H. Schroder Microvascular invasion in prostate cancer: prognostic significance in patients treated by radical prostatectomy for clinically localized carcinoma Urol Int 60 1998 17 24
55. L. Cheng, T.D. Jones, and H. Lin et al. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma J Urol 174 2005 2181 2185
56. D.S. Yee, S.F. Shariat, and W.T. Lowrance et al. Prognostic significance of lymphovascular invasion in radical prostatectomy specimens BJU Int 108 4 2011 502 507
57. A.W. Partin, L.A. Mangold, and D.M. Lamm et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium Urology 58 2001 843 848
58. O.T. Okotie, W.J. Aronson, and J.A. Wieder et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy J Urol 171 2004 2260 2264
59. B.J. Trock, M. Han, and S.J. Freedland et al. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769
60. P. Zhou, M.H. Chen, D. McLeod, P.R. Caroll, J.W. Moul, and A.V. D'Amico Predictors of prostate cancer specific mortality after radical prostatectomy or radiation therapy J Clin Oncol 23 2005 6992 6998
61. A.V. D' Amico, M.H. Chen, K.A. Roehl, and W.J. Catalona Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure J Clin Oncol 23 2005 4975 4979
62. A.V. D'Amico, J.W. Moul, P.R. Carroll, L. Sun, D. Lubeck, and M.H. Chen Surrogate end point for prostate cancer specific mortality after radical prostatectomy or radiation therapy J Natl Cancer Inst 95 2003 1376 1383
63. A. Patel, F. Dorey, J. Franklin, and J.B. de Kernion Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen J Urol 158 1997 1441 1445
64. M.N. Simmons, A.J. Stephenson, and E.A. Klein Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy Eur Urol 51 2007 1175 1184
65. O. Yossepowitch, S.E. Eggener, and F.J. Bianco et al. Radical prostatectomy for clinically localized, high-risk prostate cancer: critical analysis of risk assessment methods J Urol 178 2007 493 499
66. A.W. Partin, S. Piantadosi, and M.G. Santa et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy Urology 45 1995 831 838
67. M. Han, A.W. Partin, M. Zahurak, S. Piantadosi, J.I. Epstein, and C.W. Walsh Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer J Urol 169 2003 517 523
68. W.W. Roberts, E.J. Bergstrahl, and M.L. Blute et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy Urology 57 2001 1033 1037
69. M.W. Kattan, T.M. Wheeler, and P.T. Scardino Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer J Clin Oncol 17 1999 1499 1507
70. N. Suardi, C.R. Porter, and A.M. Reuther et al. A nomogram predicting long-term biochemical recurrence after radical prostatectomy Cancer 112 2008 1254 1263
71. M.W. Kattan, A.J. Vickers, and C. Yu et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer Cancer 115 2009 1005 1010
72. C.R. Porter, N. Suardi, and K. Kodama et al. A nomogram predicting metastatic progression after radical prostatectomy Int J Urol 15 2008 889 894
73. S.F. Slovin, A.S. Wilton, G. Heller, and H.I. Scher Time to detectable metastatic disease in patients with rising prostate-specific antigen values following surgery or radiation therapy Clin Cancer Res 11 2005 8669 8673
74. Z.A. Dotan, F.J. Bianco Jr., and F. Rabbani et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy J Clin Oncol 23 2005 1962 1968
75. G. Lughezzani, A. Briganti, and P.I. Karakiewitcz et al. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature Eur Urol 58 2010 687 700
76. S.F. Shariat, P.I. Karakiewitcz, C.G. Roehrborn, and M.W. Kattan An updated catalog of prostate cancer predictive tools Cancer 113 2008 3075 3099
77. S.F. Shariat, M.W. Kattan, A.J. Vickers, A.J. Karakiewitcz, and P.T. Scardino Critical review of prostate cancer predictive tools Future Oncol 5 10 2009 1555 1584
78. A. Vickers Prediction models in urology: are they any good, and how would we know anyway? Eur Urol 57 2010 571 573
79. M.W. Kattan Evaluating a new marker's predicting contribution Clin Cancer Res 10 2004 822 824
80. M.W. Kattan, S.F. Shariat, and B. Andrews et al. The addition of interleukin-6 soluble receptor and transforming growth factor beta improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer J Clin Oncol 21 2003 3573 3579
81. S.F. Shariat, M.W. Kattan, and E. Traxel et al. Association of pre- and postoperative plasma levels of transforming growth factor β1 and interleukin-6 and its soluble receptor with prostate cancer progression Clin Cancer Res 10 2004 1992 1999
82. J. Walz, F.K. Chun, and E.A. Klein et al. Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer J Urol 181 2009 601 607